康柏西普联合PRP治疗PDR患者的效果及对房水血管新生因子、视网膜神经纤维层厚度及视力的影响  

Effect of Compaq Cept combined with PRP in the treatment of PDR patients and its influence on aqueous humor angiogenesis factor,retinal nerve fiber layer thickness and visual acuity

作　　者：崔静琳 徐丹 CUI Jinglin;XU Dan(Departiment of Ophthalmology,Tangyin County People's Hospital,Tangyin,456150,China)

机构地区：[1]汤阴县人民医院眼科,河南汤阴456150

出　　处：《实用防盲技术》2025年第1期14-17,F0003,共5页Journal of Practical Preventing Blind

摘　　要：目的 研究康柏西普联合全视网膜光凝术(PRP)治疗增殖性糖尿病视网膜病变(PDR)患者的效果及对视网膜神经纤维层厚度、房水血管新生因子及视力的影响。方法 选取本院2020年6月至2023年6月期间107例PDR患者随机分为对照组和观察组,对照组给予PRP治疗,观察组在对照组基础上增加康柏西普治疗,在距角膜缘后约4mm垂直刺入玻璃体腔,缓慢注射0.5mg,共1次,对比两组血管新生因子、视力水平、视网膜神经纤维层厚度及并发症情况。结果 治疗后观察组血管内皮生长因子(VEGF)、基质细胞衍生因子-1 (SDF-1)水平分别为(155.28±18.36) pg/ml、(466.22±50.02) mg/L,明显低于对照组(190.23±18.33) pg/ml、(531.60±50.29) mg/L(t=9.8530、6.7419,P均<0.05);观察组治疗后上、下、颞、鼻象限内视网膜神经纤维层厚度分别为(138.10±9.18)μm、(141.62±8.49)μm、(89.44±6.74)μm、(83.89±8.02)μm,均高于对照组(127.30±8.42)μm、(130.27±7.66)μm、(81.56±6.01)μm、(77.69±5.48)μm(t=6.3387、7.2562、6.3788、4.6604,P均<0.05);治疗后观察组最佳矫正视力为(0.30±0.09),明显高于对照组(0.21±0.08)(t=5.4635,P<0.05);观察组并发症发生率5.56%(3/54)与对照组7.55%(4/53)相近(P>0.05,χ^(2)=0.0007)。结论 康柏西普联合PRP手术治疗能够抑制眼内新生血管生长,降低血管新生因子水平,有效保护视网膜神经纤维层,提高患者视力水平。ObjectiveTo investigate the efficacy of Compaq Cept combined with panretinal photocoagulation(PRP)in the treatment of proliferative diabetic retinopathy(PDR)and its effects on retinal nerve fiber layer thickness,aqueous humor angiogenesis factor and visual acuity.Methods A total of 107 patients with PDR from June 2020 to June 2023 in our hospital were randomly divided into control group and observation group.The control group was given PRP treatment,and the observation group was additionally treated with Compaplomp,and 0.5mg was injected into the vitreous chamber vertically about 4mm behind the corneal limbus,once in total.Angiogenesis factor,visual acuity level,retinal nerve fiber layer thickness and complications were compared between the two groups.ResultsAfter treatment,the levels of vascular endothelial growth factor(VECF)and stromal cell derived factor-1(SDF-1)in the observation group were(155.28±18.36)pg/ml and(466.22±50.02)mg/L,respectively.Significantly lower than control group(190.23±18.33)pg/ml,(531.60±50.29)mg/L(t=9.8530,6.7419,P<0.05);In observation group,the thickness of retinal nerve fiber layer in upper,lower,temporal and nasal quadrant after treatment was(138.10±9.18)μm,(141.62±8.49)μm,(89.44±6.74)μm,(83.89±8.02)μm,respectively.Higher than control group(127.30±8.42)μm,(130.27±7.66)μm,(81.56±6.01)μm,(77.69±5.48)μm(t=6.3387,7.2562,6.3788,4.6604,P<0.05);After treatment,the best corrected visual acuity in observation group was(0.30±0.09),which was significantly higher than that in control group(0.21±0.08)(t=5.4635,P<0.05).The complication rate in the observation group was 5.56%(3/54),similar to that in the control group 7.55%(4/53)(P>0.05,x'=-0.0007).ConclusionCombined with PRP,conbercept can inhibit the growth of intraocular neovascularization,reduce the level of angiogenesis factor,effectively protect the retinal nerve fiberlayer,and improve the visual acuity of patients.

关 键 词：视力 康柏西普 糖尿病 视网膜 血管新生因子 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]